GlycoMimetics, Inc. (GLYC)
NASDAQ: GLYC · Real-Time Price · USD
0.330
-0.049 (-12.95%)
At close: Nov 20, 2024, 4:00 PM
0.311
-0.019 (-5.67%)
Pre-market: Nov 21, 2024, 7:39 AM EST
GlycoMimetics Revenue
GlycoMimetics had revenue of $10.00K in the twelve months ending September 30, 2024. In the year 2023, GlycoMimetics had annual revenue of $10.00K, down -86.67%.
Revenue (ttm)
$10.00K
Revenue Growth
-86.67%
P/S Ratio
n/a
Revenue / Employee
$286
Employees
35
Market Cap
21.28M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionGLYC News
- 9 days ago - Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024 - PRNewsWire
- 15 days ago - GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting - Business Wire
- 20 days ago - GLYCOMIMETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of GlycoMimetics, Inc. - GLYC - Business Wire
- 22 days ago - SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFIE and GLYC on Behalf of Shareholders - PRNewsWire
- 23 days ago - GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma - Business Wire
- 23 days ago - GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint - Business Wire
- 4 months ago - GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan - Business Wire
- 6 months ago - GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) - Business Wire